18 drugs found substandard in Telangana

Hyderabad:  As many as 18 drugs, including painkillers, antibiotics and cough syrups, were found to be ‘not of standard quality’ in Telangana by the Union health ministry’s Central Drugs Standard Control Organisation (CDSCO) in March.

Out of these 18 drugs, nine batches contained only albendazole, an anti-parasitic drug commonly used to treat infections caused by worms in children, such as tapeworm, ringworm and others. While eight batches of albendazole were manufactured in Dec 2024, one was manufactured in June last year, according to the CDSCO report.

In addition, three of the NSQ drugs were labelled as misbranded, which means they contained false information.
During inspections in Feb, CDSCO declared eleven drugs as ‘not of standard quality’ (NSQ).

A senior official of the Drugs Control Administration (DCA), Telangana, said: “The drug was flagged for quality issues as it did not meet the dissolution quality test. The Madhya Pradesh-based manufacturer, which supplied eight of the nine batches of albendazole, will soon be blacklisted by the govt.”

Dr Madap Karuna, a senior paediatrician, noted that albendazole supplements are being given to children, even in schools. “It is effective in treating parasitic infections that can lead to iron deficiency, malnutrition and anaemia. It can also improve haemoglobin levels in children with parasitic infections, and albendazole is given to children at least once a year and to mothers during the third trimester.”

A drug is branded NSQ if it does not meet the requirements of the Drugs and Cosmetics Act. This is usually due to poor manufacturing, contamination and stability issues. Among other things, it leads to a loss of potency of the drug over time.

“If the drugs are of poor quality, the disease will persist. Taking NSQ drugs can lead to serious side effects. In some cases, they can have a major impact on a person’s vital organs and even lead to death. It can also lead to drug resistance in patients, making future treatment less effective,” says Dr G Srinivas, a clinical pharmacologist.

Related Posts

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

Three arrested after liquor bottles found at pharma firm

Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

Three arrested after liquor bottles found at pharma firm

Three arrested after liquor bottles found at pharma firm

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources